Related Experiment Video
Updated: Oct 13, 2025
14:45
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
6.2K
Viral alpha-synuclein knockdown prevents spreading synucleinopathy
Sindhu Menon1, Rikke H Kofoed2, Fadl Nabbouh1
1Tanz Centre for Research in Neurodegenerative Diseases, Toronto, ON M5T 0S8, Canada.
Brain Communications
|November 11, 2021
Summary
Silencing the alpha-synuclein (α-syn) gene reduced pathology and motor deficits in synucleinopathies. A moderate 50% reduction in α-syn prevented disease spread, supporting gene therapy for these neurodegenerative conditions.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Alpha-synuclein (α-syn) aggregation is implicated in Parkinson's disease and related synucleinopathies.
- A prion-like mechanism, where misfolded α-syn templates further aggregation, is hypothesized to drive disease progression.
Purpose of the Study:
- To investigate if reducing α-syn gene expression can disrupt the propagation of pathological α-syn.
- To assess the therapeutic potential of α-syn knockdown for synucleinopathies.
Main Methods:
- Utilized adeno-associated virus serotype-1 encoding microRNA targeting the α-syn gene.
- Administered unilateral intracerebral injections in a mouse model.
- Evaluated behavioral, immunohistochemical, and biochemical outcomes.
Main Results:
- Reduced α-syn gene expression led to decreased α-syn pathology and motor deficits.
- A 50% reduction in α-syn was sufficient to prevent pathology spread to distal brain regions.
- Combined data strongly support the efficacy of the intervention.
Conclusions:
- Alpha-synuclein knockdown gene therapy is a promising approach for treating synucleinopathies.
- Targeting α-syn expression can effectively mitigate disease progression and symptoms.
